A Validated Time of Flight Mass Spectrometry for Quantitative Determination of Amantadine Hydrochloride and Memantine Hydrochloride

Nahla Nour Salama*, Shudong Wang and Elham Taha

1Department of Pharmaceutical Chemistry, National Organization for Drug Control and Research (NODCAR), Egypt
2School of Pharmacy and Centre for Biomolecular Sciences, University of Nottingham, University Park, NG7 2RD, UK

Introduction

Mass spectrometry (MS) is one of the most powerful analytical techniques, particularly for pharmaceutical analysis, where good selectivity and high sensitivity are often needed. The more accurate and rapid measurements, the more quickly a drug can progress towards regulatory approval. Time-of-flight mass spectrometer (TOF-MS) delivers high sensitivity, resolution, and exact mass measurements. A variety of ion source and software options makes MS a versatile choice for a range of analytical challenges [1-4].

Amantadine hydrochloride (Am), 1-aminoadamantine (Figure 1) is an antiviral agent against infection with influenza type A virus and to ameliorate symptoms when administered during the early stages of infection, as well as in management of herpes Zoster [5]. It has mild antiparkinsonism activity and thus it has been used in the management of Parkinsonism, mainly in early disease stage and when the symptoms are mild. Amantadine is usually given by mouth as hydrochloride salt [6]. The analytical methods reported for analysis of amantadine HCl include, spectrophotometry, spectrofluorimetry [7-10], potentiometry [11], high performance liquid chromatography [12-14], gas chromatography [15-18], and capillary electrophoresis [19]. Memantine (Mem) is a structurally and pharmacologically related to antiviral amantadine (Figure 1). The drug is used to treat Parkinson’s disease, movement disorders and dementia syndrome [20,21]. Mem acts as a non competitive inhibitor of the N-methyl-D-aspartate (NMDA) receptor complex [22,23]. Several techniques were reported for determination of Mem in a variety of matrices. These methods include, spectrophotometry, spectrofluorimetry [24-26], high performance liquid chromatography (HPLC) coupled to MS [27,28] and gas chromatography-mass spectrometry[29].

The aim of this study is to develop rapid, accurate and sensitive method for simultaneous determination of Am and Mem in drug substances and products without chromatographic separation. The recommended method was not investigated previously.

TOF ES-MS analytical technique has several advantages over the aforementioned methods, where direct HPLC and GC are unsuitable, because structures of the studied drugs lack suitable UV chromophore. There is no need for method development, a short analytical time (1.5

Abstract

Introduction: Time of flight mass spectrometry was developed and validated for quantitative determination of amantadine and memantine in drug substances and products.

Materials and methods: The method was based on time of flight electron spray ionization mass spectrometry technique without preliminary chromatographic separation and made use of memantine as internal standard of amantadine, which is used as internal standard of memantine.

Results and conclusion: A linear relationship between drug concentrations and peak intensity ratios of ions of the analyzed substances is established in range of 23.80-2380.00 ng mL⁻¹ for amantadine and memantine (r= 0.998, n=6). The method is robust and reproducible with intra-and inter-assay precision (RSD % < 2.0%). The quantification limit was 23.8 ng mL⁻¹ for both drugs. The described method has advantages over the reported methods as the assay was completed in less than 2 min with high accuracy and selectivity.

Keywords: Amantadine; Memantine; Validation; Time of flight mass spectrometry; Drug products

Figure 1: Chemical structures of amantadine HCl and memantine HCl.
min), and a minimal amount of solvent being required, coupled with high sensitivity, selectivity and exact mass measurements, thereby avoiding assumptions inherent in derivatization regimes and detector response. The proposed method was validated in accordance with International Conference on Harmonization (ICH) guidelines [30].

Materials and Methods

Materials and reagents

Amantadine was purchased from Sigma Co., UK, certified to contain 99.00%, CAS No. 132112-35-7. Adamine capsule containing 100 mg amantadine per capsule (Rameda Co., Egypt) was purchased from local market. Memantine hydrochloride was kindly supplied by Adwia Co., Egypt, its purity was found to be 99.60% according to the manufacturer HPLC method [31]. Ebixa tablet containing 10.0 mg memantine hydrochloride per tablet (H. Lundbeck Co., Denmark) was purchased from the market. The following reagents and solvents were purchased and used without further purification: methanol (LC-MS grade, Fisher Scientific, UK), acetonitrile (LC-MS grade, Reidel-dehaen, UK), ultra pure water (ELGA, UK), and formic acid (Sigma-Aldrich, UK).

Apparatus and measurements

The TOF-ES-MS measurements were performed using WATERS –2795 (Waters, UK) equipped with an autosampler injector (10 µL) and Mass Lynx v 4.1. The system was operated in the following regime: electrospray voltage, 3 kv, capillary temperature, 150°C, sample solution flow rate, 0.1 mL/min. All analysis was performed in the positive ion detection mode. All samples were dissolved in a 50% solution of acetonitrile in water containing 0.1% formic acid. The calibration curves were calculated by unweighted least-squares linear regression analysis of the concentrations of the analyte versus the peak intensity ratio of ions of analyzed substance of Am (m/z=152) to that of the IS (m/z=180). As for Mem (m/z=180) to that of IS (m/z=152) was used. The concentrations of unknown samples were determined by applying the linear regression equation of the standard curve to the unknown sample’s peak intensity ratio.

Method validation

The limit of quantification of the two drugs was defined as the lowest concentration of the calibration curve.

Precision and accuracy were assessed by assaying freshly prepared solutions of the two drugs in triplicate at three concentration levels; 59.5, 119.0 and 1190.0 ng mL⁻¹. Precision is reported as relative standard deviation (RSD%) of the estimated concentrations and accuracy (Relative error%) expressed as [measured-nominal/nominal X 100].

Specificity is the ability of the method to measure the analyte response in the presence of interfering substances. For specificity determination, synthetic mixtures of different ratios of Am and Mem within the linearity range were prepared and analyzed. The recovery percent of each drug was determined.

Results and Discussion

The work includes (1) mass spectrometric identification and determinations of Am and Mem; (2) generation of the standard calibration curves; (3) quantitative analysis of Am and Mem in their drug products.

The mass spectra of Am and Mem and their internal standards are shown in Figure 2 and Figure 3. Under the conditions of TOF ES-MS in positive mode, the spectra displays intense peaks of [M + H]⁺ with ions of the highest mass to charge, e.g. m/z=152 for Am and 180 for Mem, respectively. Linearity range was found to be in concentration range of 23.80 –2380.0 ng mL⁻¹ for Am while up to 1190.0 ng mL⁻¹ for Mem (Figure 4). The results of regression data were presented in Table 1.

Linear regression analysis of the data gives the equations, A=0.0034C + 0.178, r=0.9998, for Am and A=0.0029C + 0.128, r=0.998, for Mem. Where A is the peak intensity ratio for m/z=152 for Am and 180 for Mem, respectively. Linear regression analysis of the concentration range studied (23.8–2380.0 ng mL⁻¹) for Am and up to 1190.0 ng mL⁻¹ for Mem in drug substances as stated in Table 1.

Table 2, summarizes mean values of, precision, and accuracy of intra- and inter-assay analysis. Precision and accuracy were within the
ranges acceptable for analytical and bio-analytical purposes. Intra-day precision ranged from 1.07 to 1.98% for Am while 1.03 to 2.00% for Mem in drug substances. Inter-day precision did not exceed 2.0% over the three level concentrations for three days in drug substances. The accuracy of the technique was considered satisfactory, since between-day variation over the concentration range studied was found to be less than 2%.

The specificity was assessed by analyzing laboratory prepared mixtures of both drugs in different ratios within the linearity range. The results reveal high selectivity and sensitivity of the method (Table 3).

**Application for analytical analysis of drug products**

The method was applied to determine Am and Mem in Adamine capsule and Ebixa tablets respectively. The RSD% was less than 2.0%, indicating the precision of the method; the results were presented in Table 4.
Conclusions

Analytical laboratories require accurate results, faster and more economically than ever before. This is especially true for traditional methods for rapid and non-destructive analysis techniques. Therefore the present work described a newly developed TOF-MS based method for quantitative determination of Am and Mem in drug substances and drug products without chromatographic separation. The strategy of this approach consists in direct multi-ion detection of analytes with reference to internal standards with close structures to the analyte.
method could be routinely used for analysis of Am and Mem in drug products and biological media as well as for assessing drug purity and stability.

Acknowledgments

Nahla N. Salama and Elham A. Taha would like to thank the NODCAR, Egypt and School of Pharmacy, The University of Nottingham, UK, for the visiting scholarship award.

References

1. Jayasimhulu K, Hunt SM, Kaneshiro ES, Wataneby Y, Giner JL (2007) Detection and identification of Bacillus subtilis UK02 Sphingophospholipid molecular species. J Am Soc Mass Spectrom 18: 394-403.
2. Han X, Yang K, Yang J, Fikes KN, Cheng H, et al. (2006) Factors influencing the electrospray intrasource separation and selective ionization of glycerophospholipids. J Am Soc Mass Spectrom 17: 264-274.
3. DeLong CJ, Baker PR, Samuel M, Cui Z, Thomas MJ (2001) Molecular species composition of rat liver phospholipids by ESI-MS/MS: the effect of chromatography. J Lipid Res 42: 1959-1968.
4. Koivusalo M, Haimi P, Heikinheimo L, Kostilainen R, Somerharju P (2001) Quantitative determination of phospholipid compositions by ESI-MS: effects of acyl chain length, unsaturation, and lipid concentration on instrument response. J Lipid Res 42: 663-672.
5. Prud’homme JT, Zoueva O, Weber JM (1997) Amantadine susceptibility in influenza A virus isolates: determination methods and lack of resistance in a Canadian sample. Clin Diagn Virol 8: 41-51.
6. Sweetman SC (2009) Martindale: The Complete Drug Reference. (36th edn) The Pharmaceutical Press: London UK.
7. Mahmoud AM, Khalil NY, Darwish Al, Fadi AT (2009) Selective Spectrophotometric and Spectrofluorometric Methods for the Determination of Amantadine Hydrochloride in Capsules and Plasma via Derivatization with 1,2-Naphthoquinone-4-sulphonate. Int J Anal Chem.
8. Darwish IA, Khedr AS, Askal HF, Mahmood RM (2005) Simple fluorimetric method for determination of certain antiviral drugs via their oxidation with cerium (IV). Farmaco 60: 555-562.
9. Sultan M (2004) Spectrophotometric determination of amantadine in dosage forms. Curr Topics in Anal Chem 4: 103-109.
10. Darwish IA, Khedr AS, Askal HF, Mahmood RM (2006) Simple and sensitive spectrophotometric methods for determination of amantadine hydrochloride. Journal of Appl Spectrosc 73: 792-797.
11. Florey K (1983) Analytical Profile of Drug Substances and Excipients. Academic Press, New York, NY: USA.
12. Duh TH, Wu HL, Pan CW, Kou HS (2005) Fluorimetric liquid chromatographic analysis of amantadine in urine and pharmaceutical formulation. J Chromatogr A 1088: 175-181.
13. Iwata T, Fujino H, Sonoda J, Yamaguchi M (1997) Determination of Amantadine in Human Plasma by High-Performance Liquid Chromatography with Fluorescence Detection. Anal Sci 13: 467-470.
14. Zhou FX, Kruis IS, Feibush BJ (1993) Direct determination of adamantaniame in plasma and urine with automated solid phase derivatization. J Chromatogr B Biomed Sci Appl 619: 93-101.
15. Stumpf MJ, Noall MW, Knight V (1980) Gas-chromatographic determination of amantadine in human urine. Cln Chem 26: 295-296.
16. Wesemann W, Schollmeyer JD, Sturm G (1977) Gas chromatographic and mass spectrometric studies on metabolites of adamantamine amine excreted with urine. Arzneimittelorschung 27: 1471-1477.
17. Biandatte P, Tognoni G, Belvedere G, Frigerio A, Rizzo M, et al. (1972) A gas chromatographic method for the determination of amantadine in human plasma. J Chromatogr 74: 31–34.
18. Belanger PM, Grech-Belanger O (1982) Gas-liquid chromatographic determination of plasma and urinary levels of amantadine in man. J Chromatogr 228: 327-332.

Table 1: Validation report of the proposed TOF ES-MS assay for determination of amantadine and memantine in drug substances.

| Parameters                  | Amantadine | Memantine |
|-----------------------------|------------|-----------|
| Linearly ng mL⁻¹            | 23.80 - 2380.0 | 23.80 - 1190.0 |
| LOQ ng mL⁻¹                 | 23.80      | 23.80     |

Regression equation

Slope (b)⁻¹ 3.0 x 10⁻⁴
SE of slope 9.6 x 10⁻⁶
Intercept (a) 0.187
SE of intercept 0.05
Correlation coefficient (r) 0.9998
SE of estimation 0.998

Table 2: Intra and inter-day precision and accuracy of the proposed TOF ES-MS method for analysis of amantadine and memantine in drug substances.

| Drug substances | Conc. ng mL⁻¹ | Precision RSD% | Recovery | Accuracy RE% |
|-----------------|---------------|----------------|----------|---------------|
|                 | Intra         | Inter          | Intra    | Inter         |
| Amantadine      | 59.5          | 1.89           | 2.00     | -2.67         | 1.59          |
|                 | 1190.0        | 1.07           | 1.59     | -1.58         | -2.19         |
|                 | 2380.0        | 1.94           | 1.98     | -2.11         | 2.00          |
| Memantine       | 23.8          | 1.03           | 1.96     | 1.14          | 1.97          |
|                 | 595.0         | 1.60           | 2.00     | 1.55          | 2.00          |
|                 | 1190.0        | 1.15           | 1.90     | 1.90          | 1.77          |

n = 3

Table 3: Specificity of the proposed TOF ES-MS method for simultaneous analysis of amantadine and memantine in drug substances.

| Ratio (ng mL⁻¹) | Recovery (RE) % RSD |
|-----------------|---------------------|
| Amantadine      | Memantine           | Memantine         |
| 1               | 1                   | 99.79 ± 1.07 | 99.04 ± 1.89 |
| 1               | 4                   | 100.05 ± 2.00 | 100.48 ± 1.04 |
| 2               | 1                   | 98.86 ± 1.66 | 100.18 ± 1.07 |

n = 3

Table 4: Results of analysis of amantadine and memantine in drug products by the proposed TOF ES-MS method.

| Preparations         | TOF ES-MS     | Recovery % of claimed amount | RSD% |
|----------------------|---------------|-----------------------------|------|
| Amantadine capsules  | 100 mg mL⁻¹   | 101.55 100.50               | 1.45 | 1.59 |
| Amantadine hydrochloride/capsule | 10.0 mg mL⁻¹ memantine hydrochloride/tab | 101.55 100.50 | 1.45 | 1.59 |

n = 3
19. Reichova N, Pazourek J, Polaskova P, Havel J (2002) Electrophoretic behavior of adamantane derivatives possessing antiviral activity and their determination by capillary zone electrophoresis with indirect detection. Electrophoresis 23: 259-262.

20. Schneider E, Fischer PA, Clemens R, Balzer F, Funfgeld EW, et al. (1984) Effects of oral memantine administration on Parkinson symptoms. Results of a placebo controlled multicenter study. Dtsch Med Wochenschr 109: 987-990.

21. Ditzler K (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung 41: 773-780.

22. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Memantine and Memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43: 91–104.

23. Gottelmeyer R, Pantev M, Parsons CG, Quack G (1993) Memantine in the treatment of mild to moderate dementia syndrome. Kvon, Wild ed. Spektrum der Neurorehabilitation Zuckschwerdt W, Verlag Munchen.

24. Michail K, Daabees H, Bellagy Y, Abdelkhalak M, Khamis M (2011) Spectrophotometric and spectrfluorimetric determination of memantine hydrochloride in bulk and pharmaceutical preparations. Int J Pharm Sci 3: 180-185.

25. Praveen PS, Jagathi V, Rao GD, Aparna A (2010) Extractive spectrophotometric method for the determination of memantine. Res J Pharm Bio Chem Sci 1: 222-225.

26. Jagathi V, Anupama B, Praveen PS, Rao GD (2010) Spectrophotometric determination of memantine in bulk and pharmaceutical formulations. J Curr Pharm Res 2: 17-18.

27. Suckow RF, Zhang MF, Collins ED, Fischman MW, Cooper TB (1999) Sensitive and selective liquid chromatographic assay of memantine in plasma with fluorescence detection after pre-column derivatization. J Chromatogr B Biomed Sci Appl 729: 217-224.

28. Bhavil N, Singh AS, Rita Santhakumar P, Chandrashekhar TG (2010) A Validated Stability-indicating Reverse Phase HPLC Assay Method for the Determination of Memantine Hydrochloride Drug Substance with UV-Detection Using Precolumn Derivatization Technique. Anal Chem Insights 5: 37-45.

29. Leis HJ, Fauler G, Windischhofer W (2002) Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. J Mass Spectrom 37: 477-480.

30. International Conference on Harmonization (ICH) (2005) Harmonized tripartite guideline: Validation of analytical procedures; text and methodology Q2 (R1), ICH, Geneva.

31. Manufacturer’s procedure, supplied by Adwia Co., Egypt by personal communication.